This article describes the development of the protocol for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Alzheimer's disease trial, which was developed in collaboration with the National Institute of Mental Health to assess the effectiveness of atypical antipsychotics for psychosis and/or agitation occurring in outpatients with Alzheimer's disease. The article provides a detailed description of the methodology used in the trial as well as the clinical outcomes and effectiveness measures incorporated into it, discussing the most salient issues encountered in developing the design of the trial, as well as the unique features of the trial.
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
Alzheimer's disease trial
Schneider, L. S., Ismail, M. S., Dagerman, K., Davis, S., Olin, J., McManus, D., Pfeiffer, E., Ryan, J. M., Sultzer, D. L., & Tariot, P. N. (2003). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophrenia Bulletin, 29(1), 57-72. https://doi.org/10.1093/oxfordjournals.schbul.a006991
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Pregnancy rates and clinical outcomes among women living with HIV enrolled in HPTN 052
The influence of mediators on the relationship between antenatal opioid agonist exposure and the severity of neonatal opioid withdrawal syndrome